Literature DB >> 24084745

P-glycoprotein ABCB1: a major player in drug handling by mammals.

Piet Borst, Alfred H Schinkel.   

Abstract

Mammalian P-glycoproteins are active drug efflux transporters located in the plasma membrane. In the early nineties, we generated knockouts of the three P-glycoprotein genes of mice, the Mdr1a, Mdr1b, and Mdr2 P-glycoproteins, now known as Abcb1a, Abcb1b, and Abcb4, respectively. In the JCI papers that are the subject of this Hindsight, we showed that loss of Mdr1a (Abcb1a) had a profound effect on the tissue distribution and especially the brain accumulation of a range of drugs frequently used in humans, including dexamethasone, digoxin, cyclosporin A, ondansetron, domperidone, and loperamide. All drugs were shown to be excellent substrates of the murine ABCB1A P-glycoprotein and its human counterpart, the MDR1 P-glycoprotein, ABCB1. We found that the ability of ABCB1 to prevent accumulation of some drugs in the brain is a prerequisite for their clinical use, as absence of the transporter led to severe toxicity or undesired CNS pharmacodynamic effects. Subsequent work has fully confirmed the profound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in humans. In fact, every new drug is now screened for transport by ABCB1, as this limits oral availability and penetration into sanctuaries protected by ABCB1, such as the brain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084745      PMCID: PMC3784548          DOI: 10.1172/JCI70430

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  9 in total

1.  Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs.

Authors:  H te Riele; E R Maandag; A Berns
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Authors:  U Mayer; E Wagenaar; J H Beijnen; J W Smit; D K Meijer; J van Asperen; P Borst; A H Schinkel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Authors:  A H Schinkel; U Mayer; E Wagenaar; C A Mol; L van Deemter; J J Smit; M A van der Valk; A C Voordouw; H Spits; O van Tellingen; J M Zijlmans; W E Fibbe; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Authors:  A Sparreboom; J van Asperen; U Mayer; A H Schinkel; J W Smit; D K Meijer; P Borst; W J Nooijen; J H Beijnen; O van Tellingen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 5.  Mammalian ABC transporters in health and disease.

Authors:  P Borst; R Oude Elferink
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

6.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors:  A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

8.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Authors:  A H Schinkel; E Wagenaar; L van Deemter; C A Mol; P Borst
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

Review 9.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

Authors:  Piet Borst
Journal:  Open Biol       Date:  2012-05       Impact factor: 6.411

  9 in total
  53 in total

Review 1.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

2.  Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Authors:  John K Fallon; Philip C Smith; Cindy Q Xia; Mi-Sook Kim
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

Review 3.  Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?

Authors:  Wazir Abdullahi; Thomas P Davis; Patrick T Ronaldson
Journal:  AAPS J       Date:  2017-04-26       Impact factor: 4.009

4.  Structural insight into substrate and inhibitor discrimination by human P-glycoprotein.

Authors:  Amer Alam; Julia Kowal; Eugenia Broude; Igor Roninson; Kaspar P Locher
Journal:  Science       Date:  2019-02-15       Impact factor: 47.728

5.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

6.  TLR signaling modulates side effects of anticancer therapy in the small intestine.

Authors:  Magdalena Frank; Eva Maria Hennenberg; Annette Eyking; Michael Rünzi; Guido Gerken; Paul Scott; Julian Parkhill; Alan W Walker; Elke Cario
Journal:  J Immunol       Date:  2015-01-14       Impact factor: 5.422

7.  Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.

Authors:  Guillermo Gervasini; Carlos Jara; Clara Olier; Nuria Romero; Ruth Martínez; Juan Antonio Carrillo
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

Review 8.  Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.

Authors:  Deepali Waghray; Qinghai Zhang
Journal:  J Med Chem       Date:  2017-12-28       Impact factor: 7.446

9.  Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity.

Authors:  Yi-Ting Zhang; Yu-Qi Yu; Xiao-Xia Yan; Wen-Jie Wang; Xiao-Ting Tian; Le Wang; Wei-Liang Zhu; Li-Kun Gong; Guo-Yu Pan
Journal:  Acta Pharmacol Sin       Date:  2018-11-15       Impact factor: 6.150

10.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.